[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-366616-105":59,"doc-detail-366616-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","emerging-biomarkers-in-urological-cancers-angiogenesis-and-damage-associated-molecular-pattern-signaling","Emerging Biomarkers in Urological Cancers - Angiogenesis and Damage-Associated Molecular Pattern Signaling","","The interaction between tumor cells and stroma in urological malignancies is driven by secreted and damage-associated factors that promote angiogenesis, immune modulation, and metastasis. This review synthesizes evidence on six biomarkers—GDF15, VEGF, TGF-β1, HSP90, HMGB1, and S100A9—covering their biological roles and clinical implications across renal cell carcinoma and bladder cancer. It discusses GDF15 in metabolic stress and immune regulation, VEGF in neovascularization, and TGF-β1’s tumor-suppressive and promotive effects, alongside DAMP-related signaling through pattern-recognition receptors. Comparative analyses examine diagnostic accuracy, prognostic value, and predictive capacity, and highlight potential links to ferroptosis susceptibility and non-invasive detection. The review proposes multiplex biomarker panels to support early detection, risk stratification, and personalized urological oncology, and calls for prospective validation of clinical thresholds and integration.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/emerging-biomarkers-in-urological-cancers-angiogenesis-and-damage-associated-molecular-pattern-signaling/366616/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/emerging-biomarkers-in-urological-cancers-angiogenesis-and-damage-associated-molecular-pattern-signaling/366616.png","ImageObject",300,407,{"name":92,"@type":93},"Mary Man","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-31","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":24},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Which biomarkers are covered in the review of urological cancers?","Question",{"text":112,"@type":113},"The review synthesizes evidence on six biomarkers: GDF15, VEGF, TGF-β1, HSP90, HMGB1, and S100A9, focusing on their biological functions and clinical implications.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How do DAMPs such as HMGB1 and S100 proteins contribute to the tumor microenvironment?",{"text":117,"@type":113},"They can promote an immunosuppressive microenvironment while activating innate sensors including toll-like receptors (TLRs) and RAGE, sustaining inflammation and supporting invasion and pre-metastatic niche formation.",{"name":119,"@type":110,"acceptedAnswer":120},"What is the proposed clinical value of using biomarker panels?",{"text":121,"@type":113},"Multiplexed biomarker panels are suggested to improve early detection, risk stratification, and personalized treatment by providing a more nuanced picture of tumor biology than imaging and tissue biopsy alone.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},366616,1790419823,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":24,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":26,"preview_page_count":19,"preview_urls":145},7421720224475,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Review  \nEmerging Biomarkers in Urological Cancers: Angiogenesis and Damage-Associated Molecular Pattern Signaling  \nKacper Robert Karpiuk 1, *, Grzegorz Młynarczyk 1, Joanna Matowicka-Karna 2 and Barbara Darewicz 1  \nAcademic Editor: Albrecht Reichle  \nReceived: 17 August 2025  \nRevised: 8 September 2025  \nAccepted: 13 September 2025  \nPublished: 18 September 2025  \nCitation: Karpiuk, K.R.; Młynarczyk, G.; Matowicka-Karna, J.; Darewicz, B. Emerging Biomarkers inUrological Cancers: Angiogenesis and Damage-Associated Molecular Pattern Signaling. Int. J. Mol. Sci. 2025, 26, 9130. [https://doi.org/10.3390/](https://doi.org/10.3390/)[ ](https://doi.org/10.3390/)ijms26189130  \nCopyright: © 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://creativecommons.org/](https://creativecommons.org/)[ ](https://creativecommons.org/)[licenses/by/4.0/](licenses/by/4.0/)) .  \n1 Department of Urology, Medical University of Białystok, 15-276 Białystok, Poland;  \n[mlynarz36@yahoo.pl](mlynarz36@yahoo.pl) (G.M.); [bdarewicz@op.pl](bdarewicz@op.pl) (B.D.)  \n2 Department of Clinical Laboratory Diagnostics, Medical University of Bialystok, 15-269 Białystok, Poland; [joanna.matowicka-karna@umb.edu.pl](joanna.matowicka-karna@umb.edu.pl)  \n* Correspondence: [kacper.kacper@interia.eu](kacper.kacper@interia.eu)  \nAbstract  \nThe interaction between tumor cells and stroma in urological malignancies is governed by secreted and damage-associated factors that promote angiogenesis, immune modulation, and metastasis. This review synthesizes current evidence on six biomarkers—GDF15, VEGF, TGF-β1, HSP90, HMGB1, and S100A9—detailing their biological functions and clinical implications. We discuss GDF15’s roles in metabolic stress and immune regulation, VEGF’s central role in neovascularization, and TGF-β1’s dualistic tumor-suppressive and promotive effects. We then examine damage-associated molecular patterns, highlighting HSP90’s extracellular immunomodulation, HMGB1’s signaling via pattern-recognition receptors, and S100A9’s pro-inflammatory activity through RAGE and Toll-like receptors. Comparative analyses across renal cell carcinoma and bladder cancer cohorts elucidate each marker’s diagnostic accuracy, prognostic value, and predictive capacity for targeted therapies. Notably, GDF15 and HSP90 correlate with ferroptosis susceptibility in RCC and urinary VEGF with HMGB1 increases the chances of non-invasive bladder cancer detection. We suggest that multiplexed biomarker panels could enhance early detection, risk stratification, and personalized treatment in urological oncology. We advocate for prospective studies to validate thresholds, clarify interactions, and improve clinical integration.  \nKeywords: GDF15; VEGF; TGF-β1; HSP90; HMGB1; S100A9; DAMPs (damage-associated molecular patterns); angiogenesis; renal cell carcinoma; bladder cancer  \n1. Introduction  \nCancer is a primary cause of morbidity and mortality globally, significantly influenced by the intricate interactions of genetic, environmental, and metabolic factors that collectively lead to the reprogramming of normal cells into a state of uncontrolled growth and spread [1] . The process is fundamentally reliant on the diverse array of bioactive molecules, including growth factors, cytokines, hormones, and damage-associated signals, that are secreted by both transformed cells and adjacent stromal components. The mediators coordinate essential characteristics of malignancy, such as continuous proliferative signaling, avoidance of immune detection, metabolic adaptation, and the initiation of neoangiogenesis [2–4] . The increase in obesity and related metabolic disorders is associated with the dysregulated production of factors like growth differentiation factor 15 (GDF15), potentially connecting metabolic stress to oncogenic pathways [5] . These insights highli","cbCaivtMudhQvGiX","https://ap.wps.com/l/cbCaivtMudhQvGiX","pdf",1165358,24,"English","# Abstract\n# Keywords\n# 1. Introduction\n## Molecular drivers of malignancy and emerging biomarkers\n## Roles in renal cell carcinoma and bladder cancer\n## DAMPs and innate immune signaling\n# Limitations","[{\"question\":\"Which biomarkers are covered in the review of urological cancers?\",\"answer\":\"The review synthesizes evidence on six biomarkers: GDF15, VEGF, TGF-β1, HSP90, HMGB1, and S100A9, focusing on their biological functions and clinical implications.\"},{\"question\":\"How do DAMPs such as HMGB1 and S100 proteins contribute to the tumor microenvironment?\",\"answer\":\"They can promote an immunosuppressive microenvironment while activating innate sensors including toll-like receptors (TLRs) and RAGE, sustaining inflammation and supporting invasion and pre-metastatic niche formation.\"},{\"question\":\"What is the proposed clinical value of using biomarker panels?\",\"answer\":\"Multiplexed biomarker panels are suggested to improve early detection, risk stratification, and personalized treatment by providing a more nuanced picture of tumor biology than imaging and tissue biopsy alone.\"}]","Emerging Biomarkers in Urological Cancers - Angiogenesis and Damage-Associated Molecular Pattern Signaling | PDF",1790166442,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6702a6509e077a945f5ee3bd4b5a79dc.webp",983,1390,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b6b7941c1333ee0cc397afec033e12fe.webp",982,1388,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8cc6bb3f7e81748afd2e111b0f455141.webp",981,1387,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/89239978c4d7e8c9427f6382f9c782b7.webp",980,1385]